Overview

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability of comparative studies which examine people in vivo pharmacokinetic behavior, provide the basis for clinical use. 2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese patients with locally advanced or metastatic non-small cell lung cancer.
Phase:
Phase 4
Details
Lead Sponsor:
Jiangsu Famous Medical Technology Co., Ltd.
Treatments:
Gefitinib